Agios Pharmaceuticals Receives FDA Priority Review for Mitapivat in Sickle Cell Disease

Agios Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for mitapivat to treat sickle cell disease, granting the filing a Priority Review. The FDA has established a decision goal date of November 1 for the therapy, which is already approved for other blood disorders. This development is significant for the pharmaceutical sector as it signals a potential accelerated approval path for a new sickle cell treatment despite mixed results in clinical trial endpoints.

Agios Pharmaceuticals is seeking to expand the clinical use of mitapivat, a therapy currently approved for adults with pyruvate kinase deficiency and alpha- or beta-thalassemia. The company's latest supplemental New Drug Application (sNDA) targets sickle cell disease (SCD) and is supported by data from a Phase 3 trial completed last year. While the trial successfully met its primary endpoint of hemoglobin response and key secondary endpoints regarding changes in hemoglobin concentration and indirect bilirubin, it failed to achieve a statistically significant reduction in sickle cell pain crises (SCPCs), which occur when sickle cells block blood flow and deprive organs of oxygen.

The FDA's decision to grant Priority Review indicates that the agency is sufficiently impressed by the hemoglobin-related data to fast-track the review process, despite the missed SCPC-related endpoint. This regulatory milestone sets a target action date of November 1, providing a clear timeline for a potential market entry. Investors reacted positively to the news, as the Priority Review designation suggests the FDA may be willing to grant accelerated approval based on the drug's ability to improve blood health markers in a patient population with high unmet needs.

It is important to note that the current regulatory path is for accelerated approval rather than a full traditional approval. To secure permanent standing for mitapivat in SCD, Agios must complete the REIGNITE Phase 3 Confirmatory Trial, which is currently underway. Results from this confirmatory study are not expected until next year at the earliest. For the broader pharmaceutical industry, this case highlights the regulatory flexibility the FDA may exercise regarding surrogate endpoints like hemoglobin response in the treatment of complex hematologic conditions.